• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL

Video

As treatment moves to pill-based regimens in chronic lymphocytic leukemia (CLL), the cost for patients is increasing, explained Jeff Sharman, MD, medical oncologist, Willamette Valley Cancer Institute and Research Center; medical director, The US Oncology Network.

As treatment moves to pill-based regimens in chronic lymphocytic leukemia (CLL), the cost for patients is increasing, explained Jeff Sharman, MD, medical oncologist, Willamette Valley Cancer Institute and Research Center; medical director, The US Oncology Network.

TranscriptWhat are the biggest challenges with treating chronic lymphocytic leukemia (CLL)?

The biggest issue currently for management of patients with CLL is the cost of therapy. Historically, chemoimmunotherapy approaches were given through intravenous medications and the way insurance works, often times that resulted in lower direct costs for patients. The field is moving now to an oral therapy-based regimen, and unfortunately, that’s often times associated with significant copayment barriers for patients. So, with some of our most effective treatments, which are pill-based treatments, keeping patients on therapy represents one of the biggest barriers to a successful outcome.

Related Videos
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Sarah Bajorek, PhD, BCACP, MBA.
dr monica li
dr lawrence eichenfield
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.